Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5The European Medicines Agency (EMA) is to reviewSamsung Bioepis’ Marketing Authorisation Application (MAA) for SB5. Click on this link for more information. #Pharmanews
The European Medicines Agency (EMA) is to reviewSamsung Bioepis’ Marketing Authorisation Application (MAA) for SB5. Click on this link for more information. #Pharmanews